Nerelimomab

Modify Date: 2024-04-02 19:43:55

Nerelimomab structure	Common Name	Nerelimomab
	CAS Number	162774-06-3	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Nerelimomab

Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis[1][2].

Name	Nerelimomab [usan:inn]

Description	Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis[1][2].
Related Catalog	Research Areas >> Infection
In Vivo	Nerelimomab (7.5 mg/kg，静脉输注) 在复发性菌血症的狒狒模型中保护动物免于死亡[1]。 Animal Model: Baboon model of recurrent bacteremia (Challenged with E.coli)[1] Dosage: 7.5 mg/kg Administration: i.v. infusion Result: Improved organ function and attenuated cytokine and plasminogen activator inhibitor release.
References	[1]. Schlag G, et al. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock. 1994 Jul;2(1):10-8; discussion 19-22. [2]. Cohen J, et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996 Sep;24(9):1431-40.

No Any Chemical & Physical Properties